Company intelligence

Vertex Pharmaceuticals

BiotechActiveBoston, Massachusetts, USAFounded 1989Website ↗

Is this your company? Get featured or correct your listing →

Suggest a correction

We're still building this profile — here is what Pulse has covered.

Latest Pulse

  1. Latigo Sets Terms for a $272M Nasdaq IPOLatigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.→

Coverage Timeline

newest first
  1. Aug 4, 2026IPOLatigo Sets Terms for a $272M Nasdaq IPO$272M IPO→

All Coverage

IPO

Latigo Sets Terms for a $272M Nasdaq IPO

Illustration for: Latigo Sets Terms for a $272M Nasdaq IPO
IPO$272M IPO

Latigo Sets Terms for a $272M Nasdaq IPO

Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsIambic TherapeuticsApnimedRetension PharmaceuticalsEli Lilly